Effect of Omega-3 Supplementation on Cardiometabolic Indices in Diabetic Patients with Non-alcoholic Fatty Liver Disease: a Randomized Controlled Trial

Overview

Journal BMC Nutr

Publisher Biomed Central

Specialty Nutritional Sciences

Date 2021 Dec 16

PMID 34911587

Citations 2

Authors

Abbas Ali Sangouni

Zahra Orang

Hassan Mozaffari-Khosravi

Affiliations

Soon will be listed here.

Abstract

Background: Patients with non-alcoholic fatty liver disease (NAFLD) as well as type 2 diabetes mellitus (T2DM) are at increased risk for cardiovascular diseases (CVD). Omega-3 supplementation has been proposed as a possible strategy for management of cardiometabolic risk. Cardiometabolic indices can predict and evaluate the cardiometabolic risk.

Aims: We investigated the effect of omega-3 supplementation on accurate and available cardiometabolic indices including atherogenic index of plasma (AIP), Castelli risk index I, Castelli risk index II and atherogenic coefficient (AC) in diabetic patients with NAFLD.

Methods: We conducted a double-blind, randomized controlled trial (RCT) for 12 weeks. From August 2016 to March 2017, the subjects referred to Faghihi hospital in Shiraz, Iran, were recruited. Sixty diabetic patients with NAFLD were randomly assigned into the omega-3 (2000 mg/d omega-3 capsule contained 360 mg/d eicosapentaenoic acid and 240 mg/d docosahexaenoic acid) and the placebo (liquid paraffin) groups using computer-generated random number table.

Results: Omega-3 supplementation compared to the placebo had no significant effect on AIP (- 0.11 ± 0.20 vs. -0.03 ± 0.16; P = 0.11), Castelli risk index I (- 0.25 ± 0.6 vs. -0.07 ± 0.7; P = 0.42), Castelli risk index II (- 0.24 ± 0.5 vs. -0.14 ± 0.5; P = 0.63) and AC (- 0.25 ± 0.6 vs. -0.07 ± 0.7; P = 0.42). After adjusting for confounding factors, the findings remained without change.

Conclusion: Omega-3 supplementation (2000 mg/d) for 12 weeks has no effect on cardiometabolic risk. It seems, higher doses of omega-3 can improve cordiometabolic risk. The trial was registered at Iranian Registry of Clinical Trials IRCT2016102530489N1.

Citing Articles

Increased Odds of Metabolic Dysfunction-Associated Steatotic Liver Disease Are Linked to Reduced n-6, but Not n-3 Polyunsaturated Fatty Acids in Plasma.

Frankovic I, Djuricic I, Ninic A, Vekic J, Vorkapic T, Erceg S Biomolecules. 2024; 14(8).

PMID: 39199290 PMC: 11353166. DOI: 10.3390/biom14080902.

Atherogenic Index of Plasma in Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis.

Ismaiel A, Ciobanu O, Ismaiel M, Leucuta D, Popa S, David L Biomedicines. 2022; 10(9).

PMID: 36140201 PMC: 9495578. DOI: 10.3390/biomedicines10092101.

References

He X, Wu X, Chen R, Chen C, Liu X, Wu B . Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. PLoS One. 2016; 11(10):e0162368. PMC: 5053538. DOI: 10.1371/journal.pone.0162368. View

Ainsworth B, Haskell W, Whitt M, Irwin M, Swartz A, Strath S . Compendium of physical activities: an update of activity codes and MET intensities. Med Sci Sports Exerc. 2000; 32(9 Suppl):S498-504. DOI: 10.1097/00005768-200009001-00009. View

Fernandez-Macias J, Ochoa-Martinez A, Varela-Silva J, Perez-Maldonado I . Atherogenic Index of Plasma: Novel Predictive Biomarker for Cardiovascular Illnesses. Arch Med Res. 2019; 50(5):285-294. DOI: 10.1016/j.arcmed.2019.08.009. View

Zhu F, Liu S, Chen X, Huang Z, Zhang D . Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol. 2008; 14(41):6395-400. PMC: 2766124. DOI: 10.3748/wjg.14.6395. View

Khan S, Minihane A, Talmud P, Wright J, Murphy M, Williams C . Dietary long-chain n-3 PUFAs increase LPL gene expression in adipose tissue of subjects with an atherogenic lipoprotein phenotype. J Lipid Res. 2002; 43(6):979-85. View

Izadi A, Shirazi S, Taghizadeh S, Pourghassem Gargari B . Independent and Additive Effects of Coenzyme Q10 and Vitamin E on Cardiometabolic Outcomes and Visceral Adiposity in Women With Polycystic Ovary Syndrome. Arch Med Res. 2019; 50(2):1-10. DOI: 10.1016/j.arcmed.2019.04.004. View

McEwen B, Morel-Kopp M, Tofler G, Ward C . The effect of omega-3 polyunsaturated fatty acids on fibrin and thrombin generation in healthy subjects and subjects with cardiovascular disease. Semin Thromb Hemost. 2015; 41(3):315-22. DOI: 10.1055/s-0034-1395352. View

Zibaeenezhad M, Ghavipisheh M, Attar A, Aslani A . Comparison of the effect of omega-3 supplements and fresh fish on lipid profile: a randomized, open-labeled trial. Nutr Diabetes. 2017; 7(12):1. PMC: 5865539. DOI: 10.1038/s41387-017-0007-8. View

Saleh H, Abu-Rashed A . Liver biopsy remains the gold standard for evaluation of chronic hepatitis and fibrosis. J Gastrointestin Liver Dis. 2008; 16(4):425-6. View

10.

Chalasani N, Younossi Z, Lavine J, Diehl A, Brunt E, Cusi K . The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012; 55(6):2005-23. DOI: 10.1002/hep.25762. View

11.

Kim H, Takahashi M, Ezaki O . Fish oil feeding decreases mature sterol regulatory element-binding protein 1 (SREBP-1) by down-regulation of SREBP-1c mRNA in mouse liver. A possible mechanism for down-regulation of lipogenic enzyme mRNAs. J Biol Chem. 1999; 274(36):25892-8. DOI: 10.1074/jbc.274.36.25892. View

12.

Koca T, Tugan C, Seyithanoglu M, Kocyigit B . The Clinical Importance of the Plasma Atherogenic Index, Other Lipid Indexes, and Urinary Sodium and Potassium Excretion in Patients with Stroke. Eurasian J Med. 2019; 51(2):172-176. PMC: 6592453. DOI: 10.5152/eurasianjmed.2019.18350. View

13.

Sujatha R, Kavitha S . Atherogenic indices in stroke patients: A retrospective study. Iran J Neurol. 2017; 16(2):78-82. PMC: 5526781. View

14.

Harris W, Bulchandani D . Why do omega-3 fatty acids lower serum triglycerides?. Curr Opin Lipidol. 2006; 17(4):387-93. DOI: 10.1097/01.mol.0000236363.63840.16. View

15.

Gaggini M, Morelli M, Buzzigoli E, DeFronzo R, Bugianesi E, Gastaldelli A . Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013; 5(5):1544-60. PMC: 3708335. DOI: 10.3390/nu5051544. View

16.

Lombardo Y, Chicco A . Effects of dietary polyunsaturated n-3 fatty acids on dyslipidemia and insulin resistance in rodents and humans. A review. J Nutr Biochem. 2005; 17(1):1-13. DOI: 10.1016/j.jnutbio.2005.08.002. View

17.

DeFilippis A, Blaha M, Jacobson T . Omega-3 Fatty acids for cardiovascular disease prevention. Curr Treat Options Cardiovasc Med. 2010; 12(4):365-80. DOI: 10.1007/s11936-010-0079-4. View

18.

Alwayn I, Gura K, Nose V, Zausche B, Javid P, Garza J . Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Pediatr Res. 2005; 57(3):445-52. DOI: 10.1203/01.PDR.0000153672.43030.75. View

19.

Tkac I . Metabolic syndrome in relationship to type 2 diabetes and atherosclerosis. Diabetes Res Clin Pract. 2005; 68 Suppl1:S2-9. DOI: 10.1016/j.diabres.2005.03.002. View

20.

Kromhout D, Yasuda S, Geleijnse J, Shimokawa H . Fish oil and omega-3 fatty acids in cardiovascular disease: do they really work?. Eur Heart J. 2011; 33(4):436-43. PMC: 3279313. DOI: 10.1093/eurheartj/ehr362. View